Literature DB >> 2164822

Deficiencies of human C3 complement receptors type 1 (CR1, CD35) and type 2 (CR2, CD21).

M D Kazatchkine1, D T Fearon.   

Abstract

CR1 (CD35) and CR2 (CD21) are structurally related integral transmembrane glycoproteins that function as cellular receptors for human C3b and C3dg, respectively. The primary sequence of the most common structural allotype of CR1 and that of CR2 have been established, and ligand binding on the molecules has been mapped. CR1 and CR2 genes are located in close vicinity in the RCA locus of chromosome 1. CR1 has a wide cellular/tissular distribution and mediates a variety of biologic functions, including the transport of C3-bearing immune complexes on erythrocytes, enhancement of phagocytosis, induction of IL-1 secretion and enhancement of B-cell differentiation. Expression of CR2 is restricted to B lymphocytes and follicular dendritic cells. The receptor modulates B-cell growth. CR2 also serves as the receptor for EBV and determines the cellular tropism of the virus. This review discusses the molecular biology and functional characteristics of CR1 and CR2. It focuses on alterations of expression of the receptors in disease, with particular emphasis on the genetic and acquired factors that contribute to the defective expression of CR1 in patients with systemic lupus erythematosus.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2164822

Source DB:  PubMed          Journal:  Immunodefic Rev        ISSN: 0893-5300


  6 in total

Review 1.  Progress in molecular and genetic studies of IgA nephropathy.

Authors:  J Novak; B A Julian; M Tomana; J Mesteck
Journal:  J Clin Immunol       Date:  2001-09       Impact factor: 8.317

Review 2.  Clinical utility of complement assessment.

Authors:  A E Ahmed; J B Peter
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

Review 3.  Complement deficiency and immune complex disease.

Authors:  K A Davies; J A Schifferli; M J Walport
Journal:  Springer Semin Immunopathol       Date:  1994

4.  Soluble CR1 therapy improves complement regulation in C3 glomerulopathy.

Authors:  Yuzhou Zhang; Carla M Nester; Danniele G Holanda; Henry C Marsh; Russell A Hammond; Lawrence J Thomas; Nicole C Meyer; Lawrence G Hunsicker; Sanjeev Sethi; Richard J H Smith
Journal:  J Am Soc Nephrol       Date:  2013-08-01       Impact factor: 10.121

5.  Peripheral catabolism of CR1 (the C3b receptor, CD35) on erythrocytes from healthy individuals and patients with systemic lupus erythematosus (SLE).

Authors:  J H Cohen; H U Lutz; J L Pennaforte; A Bouchard; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

6.  Autoantibodies against complement receptor 1 (CD35) in SLE, liver cirrhosis and HIV-infected patients.

Authors:  S Sadallah; C Hess; M Trendelenburg; C Vedeler; M Lopez-Trascasa; J A Schifferli
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.